Raised twice. Fell anyway.
Novo raised its 2026 guidance twice in six months and the stock fell 5% on the news. The market has stopped grading Novo on how much it sells and started grading it on what it can charge.
On August 5, Novo Nordisk raised its full-year guidance for the second time in six months, on a quarter that grew 7% adjusted with operating profit up 11.
The stock fell 5%.
That is not a market being irrational. That is a market that has stopped grading Novo on how much it sells and started grading it on what it can charge. This edition is about the difference.
The upgrade arc
Follow the guidance, because on paper it is a recovery.
| guided | range |
|---|---|
| February | -5 to -13% |
| May 6 | -4 to -12% |
| August 5 | 0 to -6%, sales and operating profit |
February’s guide was the first backward one of Novo’s GLP-1 era. May narrowed it. August raised it again, and this time the top of the range touches zero, for sales and operating profit both.
The quarter underneath: sales of DKK 78.49 billion, up 3% at constant currency, up 7% adjusted. Adjusted operating profit up 11%. By every headline number, the year Novo warned about in February is going better than promised.
The market’s answer, within the day: down 5%.
For contrast, Eli Lilly reported the same morning, beat, and raised its 2026 revenue guidance to $85 to 87 billion from $82 to 85 billion. And read Lilly’s release closely: it concedes “lower realized prices” on both of its flagships too, including its announced cash-pay cuts.
That is the thesis in one pairing. The whole category is repricing. The difference is that Lilly’s volume outruns the erosion and Novo’s does not, and the market graded both accordingly.
The erosion ledger
Here is what investors read under Novo’s headline, line by line.
US injectable Wegovy sales fell 22%, on lower realized prices. Not fewer patients. Lower prices per patient, in the product’s home market.
Ozempic’s US pricing is eroding 10 to 15% a year, per the CFO. Adjusted gross margin came in at 78.2%, down from 82.7%, including a one-time DKK 3 billion manufacturing charge. Headcount is down 15% year over year, against a DKK 8 billion cost-transformation target. That last number is how you raise operating-profit guidance while your prices fall: you remove the costs faster than the prices leave.
Growth, meanwhile, has one engine. The Wegovy pill is running above 265,000 US prescriptions a week and passed 5 million since its January launch. It is the best thing on Novo’s income statement, and even it came in slightly under consensus for the quarter, DKK 3.22 billion against 3.27 expected.
It is also winning its own fight. Lilly’s rival pill, Foundayo, booked $98 million in its first full quarter, below forecasts, against roughly $500 million equivalent for Novo’s pill in the same period. The 9 to 1 script gap we reported in July now has a 5 to 1 revenue confirmation.
Edition 1 wrote it in July, before any of these numbers printed: “Volume can keep growing while revenue falls. That is not a paradox. That is what a commodity looks like being born.”
This quarter is that sentence wearing financial statements. Volume: up, everywhere. Realized prices: down 22% in the flagship, eroding double digits in the diabetes brand, gross margin down four and a half points. The commodity is no longer being born. It is here, and Novo’s own guidance now assumes it.
The line Novo said quietly
Buried in the second-half caution, management named the reason to stay careful: semaglutide patent expiries in Canada and Brazil, against a DKK 5 billion rebate comparison from last year. That is the first time we have heard the company pair them, the patent collapse framed as multi-country by Novo itself.
We have been reporting the Canadian half of that sentence since this brief started; the full dated record is on the timeline. And Brazil turns out to be further along than the careful phrasing suggests: the patent there fell in March, the Superior Court fight over extending it is already over, and five companies are queuing generics. It is now a named thread on this beat: approvals, launches, first prices.
And one calendar we set is now live. Edition 4 argued the launch window for Plosbrio and Poviztra, Novo’s renamed twins, opens in the two weeks after earnings, once the CFO no longer has to explain a self-cannibalizing launch on results morning. Earnings have passed. That window runs through roughly August 19.
We checked Health Canada’s database on August 6, the morning after results: all 17 twin DINs still read Approved, not Marketed, 227 days after approval. Sevmia, the first generic Wegovy, also still sits unpriced and unlisted. Both twins were still Approved when we looked again before sending this. We check weekly, and the day anything flips, you will read it here first.
One promise while the clock runs. We put a date on this call in edition 4, so the call gets graded in public.
If August 19 passes and the twins are still sitting in the database, you will read it here first, along with what we got wrong about the logic. A brief that only reports its hits is an ad.
The watch continues either way, because waiting for Sevmia’s number was always the core of the read, and Sevmia has not printed one yet.
Watching for
- The DPD tripwire, through August 19. The twins’ post-earnings window from edition 4 is open; database checked weekly, all 17 DINs Approved as of August 6.
- Sevmia’s price and stocking. The late-July-to-August window is more than half spent with no database movement.
- Brazil’s generic timeline, the newest thread on the beat. The patent fell in March and five companies are queuing: watch the approvals, the launches, and the first prices.
That is the brief. Same time Tuesday.